SCHEDULE: Armistice Capital Discloses 9.99% Stake in GeoVax Labs

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 9.99% in GeoVax Labs, Inc. common stock as of March 31, 2026.

Summary

• Armistice Capital, LLC and Steven Boyd collectively hold 291,155 shares of GeoVax Labs, Inc. common stock.
• This holding represents 9.99% of the class of securities.
• The filing is an amendment to a Schedule 13G, indicating a change in beneficial ownership.
• Armistice Capital, LLC acts as the investment manager for the Master Fund, which is the direct holder of the shares.
• Steven Boyd, as the managing member of Armistice Capital, LLC, may also be deemed to beneficially own these shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It's a standard disclosure of a significant ownership stake, which doesn't inherently signal positive or negative performance for GeoVax Labs itself, but rather reflects an investment decision by Armistice Capital.

Positives

• Armistice Capital, LLC and Steven Boyd have disclosed a significant ownership stake, which could signal confidence in GeoVax Labs' future prospects.
• The 9.99% ownership is just below the threshold that would typically trigger a more detailed Schedule 13D filing, suggesting a passive investment approach for now.

Negatives

• The filing does not provide specific details on the acquisition cost or the exact timing of the share purchases, making it difficult to assess the immediate financial impact for the reporting persons.
• The Master Fund disclaims beneficial ownership due to its investment management agreement with Armistice Capital, which adds a layer of complexity to the ownership structure.

Risks

• Potential for increased scrutiny from regulators or other investors due to the significant ownership stake.
• If Armistice Capital's investment strategy shifts, a large sell-off of shares could negatively impact GeoVax Labs' stock price.

Future Outlook

The filing itself is a disclosure of current ownership and does not contain forward-looking statements or guidance from GeoVax Labs, Inc. The future outlook for the company would be derived from other company disclosures.

Management Comments

• Armistice Capital, LLC exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund.
• Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund.
• The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.
• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

Industry Context

StockSavvy.ai notes that significant stake disclosures by investment firms like Armistice Capital are common in the biotechnology sector, often indicating a belief in the company's technology or market potential. This filing places GeoVax Labs within the typical landscape of companies attracting institutional investor interest.

Stakeholder Impact

• Shareholders: May view the increased institutional interest positively, potentially leading to increased liquidity or future strategic partnerships. However, a large sell-off by Armistice Capital could negatively impact share price.
• Management and Employees: May see this as validation of the company's strategy, potentially boosting morale. However, it also brings increased scrutiny from a significant shareholder.
• Creditors: The filing does not directly impact creditors, but any significant change in the company's financial health, potentially influenced by major shareholders, could be a concern.

Next Steps

• Monitor future filings from Armistice Capital, LLC and Steven Boyd for any changes in their beneficial ownership of GeoVax Labs, Inc. stock.
• Observe GeoVax Labs, Inc.'s performance and strategic developments to understand the basis for Armistice Capital's investment.

Key Dates

Keywords

GeoVax Labs, Armistice Capital, Schedule 13G, Beneficial Ownership, SEC Filing, Common Stock, Investment Management, Steven Boyd